Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wuling Capsule in Adolescents With Mild-to-Moderate Mood Disorders and Attention Decline (Real-World Observational Study)
ChiCTR2600123642Phase 4Not yet recruiting
- Sponsor
- Huzhou Third People's Hospital
- Start
- Apr 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of wulingshen in major depressive disorder (MDD), anxiety disorder and attention deficit hyperactivity disorder (ADHD), sponsored by Huzhou Third People's Hospital. Primary endpoint: Attention span error rate at 6 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
wulingshen
03
Conditions
major depressive disorder (MDD)anxiety disorderattention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on ChiCTR2600123642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123642.